Atrial Fibrillation, Deep Vein Thrombosis, Heart Valve Disease, Pulmonary Embolism
Conditions
Keywords
warfarin metabolism, pharmacogenetics, CYP2C9, genotyping, VKORC1, CYP4F2, anticoagulation, atrial fibrillation, deep vein thrombosis, pulmonary embolism, Artificial Heart Valve
Brief summary
The purpose of this study is to determine whether pharmacogenetic guided dosing of warfarin is promising for the improvement of efficiency, therapeutic efficacy, and, especially, safety of warfarin therapy than a dosing regimen without the pharmacogenetic information in Chinese patients initiated on warfarin anticoagulation.
Detailed description
Warfarin is the most widely used oral anticoagulation drug for preventing and treating thromboembolic events, but there is greater than 10-fold interindividual variability in the dose required to attain a therapeutic response. In 2007, the US Food and Drug Administration updated the label of warfarin, recommending consideration of pharmacogenetic information which has been confirmed to contribute significantly to the variability in warfarin dose requirements. Thereafter, multiple pharmacogenetic dosing algorithms were constructed to predict warfarin dose by integrating clinical and genetic factors. Taken together, approximately between one-third and one- half of the variability in warfarin dose could be explained by the proposed algorithms. However, the potential benefit of these dosing algorithms in terms of their safety and clinical utility has not been adequately investigated in randomised settings in Chinese patients. Study objectives: 1. To apply routine pharmacogenetic (PG)-guided dosing of warfarin in clinical practice in Chinese patients. 2. To compare the percentage out-of-range (%OOR) International Normalized Ratios (INRs) during the first 3 month of warfarin therapy using PG-guided dosing with historical standard (STD), empiric dosed controls. 3. To compare the cost effectiveness, number of thromboembolic and bleeding events, time within therapeutic INR range, time to reach stable dose and number of supratherapeutic INR peaks during the first 3 month of warfarin therapy using PG-guided dosing with historical standard (STD), empiric dosed controls. Study design: This is a prospective, randomized study of Chinese patients who are to initiate chronic warfarin anticoagulation for specific, qualifying clinical reasons (i.e., atrial fibrillation, Deep vein thrombosis/pulmonary embolism, or Prosthetic valve replacement). Qualifying patients will be consented and randomized to an individualized, pharmacogenetic guided warfarin-dosing regimen (PG group) or to standard care (without knowledge of genotype)(STD group). All patients will receive a baseline INR. For patients in PG group, a maintenance dose for each patient will be predicted by the pharmacogenetic algorithm derived previously in Chinese. A maintenance dose of 3 mg/day will designed to each patients in STD group. The starting dose of warfarin that is twice the assigned daily maintenance dose will be prescribed on the first and second days, and then the dose will revert to the assigned maintenance dose. Study duration: Each patient will participate for at least 3 months.
Interventions
OTHERGenotype-guided warfarin dosing
Applying a Pharmacogenetic-guided warfarin dosing algorithm derived from Chinese to determine the daily maintenance dose of warfarin, based on clinical factors (age, sex, body surface area, etc.), and VKORC1, CYP2C9 and CYP4F2 genotypes, to individualize the dosing of warfarin.
A Empiric fixed warfarin dose of 3 mg/day was given to the patients for at least 3 days. Following doses were adjusted according to the INR measurement.
Sponsors
Chinese PLA General Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Patients ≥18 years old * Patients initiated on warfarin for venous thromboembolism, pulmonary embolism, atrial fibrillation or heart valve replacement that require long- term oral anticoagulation with target INR ranged 1.5-3.0 for at least 3 months * Ability to attend scheduled visits * Signed informed consent
Exclusion criteria
* Non-eligible subject * Pregnant,lactating or of child-bearing potential women * Patients with severe co-morbidities (e.g., renal insufficiency/creatinine \> 2.5 mg/dL,hepatic insufficiency, active malignancy, terminal disease) * Known genotype CYP2C9 or VKORC1 at start of the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| A comparison between the pharmacogenetic and standard arms of the per-patient percentage of out-of-range INRs (<1.5, >3). | 3 months |
Secondary
| Measure | Time frame |
|---|---|
| Time to the first supratherapeutic INR | 3 months |
| The proportion of time within the therapeutic INR range | 3 months |
| The proportion of patients reaching therapeutic INR on days 5 and 8 | 3 months |
| The total number of INR measurements and number of dose adjustments made | 3 months |
| Proportion of INRs > 4 | 3 months |
| Major bleeding events | 3 months |
| Minor bleeding events | 3 months |
| Thromboembolic complications | 3 months |
Countries
China
Contacts
Primary ContactTong Yin, Dr.
Backup ContactXiaoqi Li, Dr.
Outcome results
None listed